If you’ve ever fought to get a prescribed biologic or advanced therapy covered, only to be told “you must try this first”, you’ve encountered step therapy, sometimes called “fail-first”. In 2026, step therapy remains a major hurdle for patients and practices, but recent state and federal activity is shaping how these policies operate and how coordinators can navigate them effectively.

What Is Step Therapy and Why It Matters

Step therapy is an insurer practice that requires patients to first try one or more insurer-preferred medications before approving the treatment their clinician originally prescribed. The intent is cost control, but the result can be treatment delay, disease progression, increased administrative burden, and for some patients, real harm.

For chronic immune-mediated conditions common in dermatology, such as psoriasis, atopic dermatitis, or hidradenitis suppurativa, timely access to the right medication can dramatically affect outcomes. Step therapy protocols can prolong disease activity and complicate clinical decision-making, particularly when “fail first” requirements aren’t rooted in evidence-based medicine.

State Laws: Patchwork Protections Across the Country

In 2026, the landscape of step therapy legislation remains varied — and mostly driven by state action:

• Many states have step therapy reform laws that require health plans regulated by the state to include clear exception or override processes. These laws aim to protect physician judgment and patient safety by mandating transparency and timelines for insurer responses.
• Recent examples include New Jersey’s step therapy reform law, effective Jan. 1, 2026, which places guardrails on how insurers use step therapy protocols in state-regulated plans, including Medicaid.
• New legislation being introduced in states like Rhode Island (2026) seeks to expand step therapy exception rights by explicitly allowing providers to request and secure exceptions when step protocols are inappropriate.

Despite these advances, state protections vary widely in:

• what types of plans they cover (many don’t apply to self-funded employer plans),
• which therapies an exception applies to,
• and how quickly insurers must respond to exception requests.

That means two patients living just a few miles apart may face very different access journeys depending on how their state regulates step therapy.

The Federal Picture: Safe Step Act & Broader Reform

While many states are modernizing step therapy protections, a federal solution remains in play.

The Safe Step Act, reintroduced in the 119th Congress, would amend federal law to require group health plans subject to ERISA to provide a clear, prompt, and transparent exception process for step therapy protocols. If enacted, this would standardize protections for millions of Americans covered by employer plans, something state laws can’t do on their own.

Under proposals like the Safe Step Act:

• insurers would be required to accept exceptions when a step therapy drug is likely to be ineffective,
• contraindicated,
• likely to cause harm,
• or delay treatment that risks significant clinical deterioration.

This potential federal guardrail highlights a crucial shift: from simply navigating step therapy to advocating for simplified, standardized processes that respect clinician judgment.

What This Means for Your Patients

For patients, these reforms can mean:

• fewer unnecessary treatment delays,
• clearer pathways to the right therapy,
• stronger documentation support when clinicians request exceptions,
• and ideally, fewer administrative hurdles between diagnosis and disease control.

However, because protections are still uneven:

• step therapy protocols remain in effect for many plans,
• self-funded plans are often exempt from state laws,
• and insurers still wield significant formulary control.

That’s why patient education and advocacy, especially around exception processes, are vital.

What Coordinators Can Do Right Now

As a coordinator on the front lines of access work:

Know your state’s law. Understand whether your state requires insurers to offer exception paths, how quickly they must respond, and which plans are covered.

Document thoroughly. When seeking an exception, clinical narratives that align with state criteria, such as risk of harm or contraindications, strengthen your case.

Use available tools. National associations offer letter templates and workflows that ease exception and appeal submissions.

Educate patients. Help them understand why step therapy exists, how it impacts their care, and what the exception process looks like.

Track outcomes. Internal data on approval timelines, exceptions granted, and patient response milestones can support operational improvements and advocacy.

Takeaway

In 2026, step therapy isn’t going away, but the way it’s regulated is evolving. State reform efforts and federal proposals like the Safe Step Act signal momentum toward more patient-centric, clinically aligned step therapy processes. For practices and coordinators, staying informed and proactive isn’t just helpful, it’s essential for ensuring patients receive timely, effective care.